Results 111 to 120 of about 477,894 (133)

Crystal structure of raltegravir potassium, C₂₀H₂₀FKN₆O₅

Powder Diffraction, 2015
The crystal structure of the potassium salt of raltegravir has been solved and refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Raltegravir potassium crystallizes in space groupP21/c(#14) witha= 15.610 59(9),b= 8.148 19(3),c= 16.125 97(6) Å,β= 94.1848(5)°,V= 2045.72(1) Å3, andZ= 4.
James A. Kaduk, Kai Zhong, Amy M. Gindhart, Thomas N. Blanton   +3 more
semanticscholar   +4 more sources

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Raltegravir Potassium

Journal of Pharmaceutical Sciences
The present monograph discusses the possibility of BCS-based biowaivers for immediate release pharmaceutical products containing raltegravir potassium, which is used to treat human immunodeficiency virus (HIV) infections. Raltegravir potassium can be assigned to BCS class II or IV since this compound has low solubility and uncertain permeability ...
Atsushi Kambayashi, Masaki Iida, Makoto Ishihara, Yoshimitsu Takahashi, Bertil Abrahamsson, Naseem A. Charoo, Rodrigo Cristofoletti, Peter Langguth, Mehul Mehta, Alan Parr, James E. Polli, Vinod P. Shah, Jennifer B. Dressman   +12 more
semanticscholar   +4 more sources

Development of a Second-Generation, Highly Efficient Manufacturing Route for the HIV Integrase Inhibitor Raltegravir Potassium

Organic Process Research & Development, 2010
A manufacturing route for the synthesis of raltegravir potassium 1 was developed via a thermal rearrangement of amidoxime DMAD adducts 6 to construct the key, highly functionalized hydroxypyrimidin...
Guy R. Humphrey, Philip J. Pye, Yong‐Li Zhong, Rémy Angelaud, David Askin, Kevin M. Belyk, Peter E. Maligres, Danny Mancheno, Ross A. Miller, Robert A. Reamer, Steven A. Weissman   +10 more
semanticscholar   +4 more sources

A Polar Radical Pair Pathway To Assemble the Pyrimidinone Core of the HIV Integrase Inhibitor Raltegravir Potassium

Angewandte Chemie, 2008
The UN and WHO currently estimate that 40 million people are living with HIV/AIDS worldwide. Combination therapies using reverse transcriptase and protease inhibitors have been highly successful, but the emergence of drug resistance prompts a search for ...
Philip J. Pye, Yong‐Li Zhong, Gavin O. Jones, Robert A. Reamer, K. N. Houk, David Askin   +5 more
semanticscholar   +6 more sources

DoE-Based Solid Self-microemulsifying Drug Delivery System (S-SMEDDS) Approach for Improving the Dissolution Properties of Raltegravir Potassium

Journal of Pharmaceutical Innovation, 2022
Sourabhkumar Jain, Kiran Dudhat, Moinuddin Soniwala, Nirav Kotadiya, Dhaval Mori   +4 more
semanticscholar   +3 more sources

Synthesis of the HIV Integrase Inhibitor Raltegravir Potassium

Synfacts, 2011
Enantioselective Total Syntheses of Three Cladiellins (Eunicellins): A General Approach to the Entire Family of Natural ...
Contributor Philip Kocienski
semanticscholar   +4 more sources

Raltegravir Potassium

, 2021

openalex   +2 more sources

Raltegravir Potassium – Rufinamide

, 2018

openalex   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma

Chemical Biology and Drug Design, 2023
Raltegravir, the first integrase inhibitor approved for the treatment of HIV infection, has been implicated as a promising potential in cancer treatment.
Dilara Akcora-Yildiz, N. Gonulkirmaz, T. Ozkan, M. Beksaç, A. Sunguroglu   +4 more
semanticscholar   +1 more source

Hepatic steatosis associated with exposure to elvitegravir and raltegravir.

Clinical Infectious Diseases, 2021
Moderate-to-severe hepatic steatosis in people living with HIV without viral hepatitis or excessive alcohol intake was associated with cumulative exposure to stavudine, elvitegravir and raltegravir.
D. Kirkegaard-Klitbo, M. T. Thomsen, M. Gelpi, F. Bendtsen, S. Nielsen, T. Benfield   +5 more
semanticscholar   +1 more source